Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05909904 · ClinicalTrials.gov registry record · Phase 2

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

A Phase 2 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma, sponsored by BeiGene.

Active
Registry status
Phase 2
Development phase
160
Enrollment target
20
Study locations

NCT05909904 is a Phase 2 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma that is active but no longer recruiting, run by BeiGene. The registered enrollment target is 160 participants, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (38% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05909904, a Phase 2 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by BeiGene.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
160 participants
Enrollment target
20
Study locations

Study Summary

This study is designed to evaluate the efficacy and safety of tislelizumab and tislelizumab in combination with investigational agent(s) in first-line recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

Conditions Studied

Head and Neck Cancer Head and Neck Squamous Cell Carcinoma

Interventions

  • DRUG Tislelizumab
  • DRUG LBL-007
  • DRUG BGB-A425

Study Locations (20)

California

  • Valkyrie Clinical Trials - Los Angeles
  • Stanford Medicine - Stanford

Florida

  • Florida Cancer Specialist Research Institute Lake Nona - Orlando
  • Florida Cancer Specialist Research Institute Panhandle - Tallahassee

Washington

  • Cancer Care Northwest - Spokane Valley
  • Northwest Cancer Specialist, Pc(Us Oncology Research) - Vancouver

New South Wales

  • Nepean Hospital - Kingswood
  • North Shore Private Hospital - St Leonards

Queensland

  • Gold Coast Private Hospital - Gold Coast
  • Greenslopes Private Hospital - Greenslopes

Colorado

  • Rocky Mountain Cancer Centers, Llp(Us Oncology Research) - Lone Tree

Kentucky

  • University of Kentucky Markey Cancer Center - Lexington

Virginia

  • Oncology and Hematology Associates of Southwest Virginia, Inc (Us Oncology Research) - Blacksburg

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2023-07-21
Est. Completion 2026-05-28
Phase Phase 2

Sponsor

BeiGene

65 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05909904

The ClinicalTrials.gov registry entry for NCT05909904 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (38% lower). The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 3 interventions - of which Tislelizumab is the first listed.

NCT05909904 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Florida, Washington.

Frequently Asked Questions

What is clinical trial NCT05909904 about?

NCT05909904 is a clinical study titled "A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma". This study is designed to evaluate the efficacy and safety of tislelizumab and tislelizumab in combination with investigational agent(s) in first-line recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

What is the current status of trial NCT05909904?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2023-07-21. Estimated completion is 2026-05-28.

What conditions does trial NCT05909904 study?

This clinical trial studies the following conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma.

What interventions are being tested in trial NCT05909904?

The interventions under investigation include: Tislelizumab (DRUG), LBL-007 (DRUG), BGB-A425 (DRUG).

Who is sponsoring clinical trial NCT05909904?

This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05909904 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Kentucky, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Head and Neck Cancer

All registered trials for this condition

Head and Neck Squamous Cell Carcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.